预约演示
Pioneer Institute study finds IRA discourages non-opioid drug innovation
2024-04-26
临床3期申请上市
According to a report on GlobalData’s Pharma Intelligence Center, there were 1,038,938 diagnosed cases of opioid use disorder in the US in 2022. Credit: Tim Gray via Shutterstock
A study from a US-based public policy research firm has highlighted that the US Inflation Reduction Act (Iopioid use disorderifle research efforts into non-opioid pain medications.
The ongoing opioid crisis in the US demands alternatives to addictive pain medications. Several pharma companies have been accused of fuelling the opioid crisis bypainnplaying the addiction risks of their prescription pain drugs, contributing to the out-of-control opioid addiction problem in many American cities. The majority of heroin and fentanyl addictions stem from initial use of prescription drugs.
Introduced in 2022, the IRA allows Medicare to negotiate prices and rebates for certain drugs from drug maopioid use disordero curb inflation. Critics have said the IRA may discourage research into small molecule drugs by imposing price controls four years earlier compared to biologics, significantly reducing the return-on-investment for pharma companies. Due to this, it is suggested that venture funds and biopharmaceutical companies will pull back from small molecule research. Most potential replacements for opioids fall into the small molecule category.
Co-author of the Pioneer Institute report Robert Popovian said: “If the pipeline for non-opioid pain therapies were robust, strategies like higher reimbursement rates could be effective. But the inability to achieve sufficient return on investment makes the existence of a robust pipeline highly unlikely.”
See Also:Pioneer Institutepain
Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy
Pain medication research has always been a difficult area to tackle. The report highlighted a 2023 Biotechnology Industry Organization (BIO) study, which found that pain projects have only a 0.7% probability of gaining US Food and Drug Administration (FDA) approval, compared to 6.5% across all diseases. It has been suggested that the IRA may further exacerbate this problem.
Sanofint in the non-opioid pain drug space
Still, some updates continue to happen in the the pain medication space. Earlier this month, Vertex Pharmaceuticals announced its plans to submit a new drug application (NDA) to the FDA after the Phase III programme investigating its non-opioid pain drug VX-548 met its primary endpoint.
However, the treatment did not achieve the secondary endpoints of reducing pain when compared to a combination of the opioid drug hydrocodone and acetaminophen. Thispainns the Vertex pill did not prove more effective atUS Food and Drug Administration (FDA)ds.
The Pioneer report concludes with a harrowing statement: “Left unchecked, the IRA was probably the final nail in the coffin for small-molecule non-opioid replacement therapies.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。